Generated by AI
AnaptysBio, Inc. is a biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases. AnaptysBio develops and manages antibody-based programs designed to modulate immune pathways involved in chronic immune dysfunction, with current work spanning clinical and preclinical candidates as well as royalty and collaboration assets. Its portfolio includes investigational therapies aimed at conditions such as rheumatoid arthritis, ulcerative colitis, atopic dermatitis, celiac disease, eosinophilic esophagitis, and generalized pustular psoriasis. The company also manages financial collaborations tied to partnered assets, reflecting a business model that combines internal drug development with externally partnered programs. Based in San Diego, California, AnaptysBio plays a role in the biotechnology market as a specialist in immune cell modulation and antibody therapeutics.
Website10770 Wateridge Circle
San Diego, CA, 92121
United States
The latest articles about ANAB.
Summary of Apr 27's posts. Generated by AI.
Summary of Feb 13's posts. Generated by AI.
Summary of Feb 11's posts. Generated by AI.
Summary of Nov 21's posts. Generated by AI.
Investors talking about ANAB also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.